Chhavi Gupta1, Akash Sali2, Binyun Ma3, Alexandra Jackovich4, Sarmad Sadeghi3, David Quinn3, Parkash Gill4, Inderbir Gill5. 1. Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States; Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States. Electronic address: drchhavi26@gmail.com. 2. Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States; Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States. 3. Department of Medicine, USC Norris Comprehensive Cancer Centre, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States. 4. Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States; Department of Medicine, USC Norris Comprehensive Cancer Centre, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States. 5. Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Abstract
BACKGROUND: Prostate cancer is managed by surgery, androgen deprivation and cytotoxic chemotherapy. Targeted therapy is emerging as an important pillar in cancer therapeutics, however, efficacy in prostate cancer has been limited. Eph-ephrin is a novel pathway that is upregulated in prostate cancer and promotes the initiation and progression of cancer. The aim of this study was to determine the immunohistochemical expression of ephrinB2 in prostate adenocarcinoma. METHODS: A tissue microarray comprising of prostate adenocarcinoma of different grade groups was stained with a monoclonal anti-ephrinB2 antibody (Abcam, AB201512). The tumor and endothelial cells expressing the ephrinB2 positivity were noted. The statistical analysis was performed to determine the difference in expression based on grade groups and the TNM stage. RESULTS: EphrinB2 was expressed in 40 out of 72 cases (55.5 %) of prostate adenocarcinoma and was predominantly negative in the normal prostatic tissue. There was no significant difference in the expression of ephrinB2 in various grade groups (p = 0.7) or stages (p = 0.6). CONCLUSIONS: EphrinB2 is expressed in a significant number of prostate adenocarcinoma regardless of grade and stage. Hence, there is a potential to target this molecule in the low-grade tumors with localized disease as well as high grade, high volume tumors with metastatic disease.
BACKGROUND: Prostate cancer is managed by surgery, androgen deprivation and cytotoxic chemotherapy. Targeted therapy is emerging as an important pillar in cancer therapeutics, however, efficacy in prostate cancer has been limited. Eph-ephrin is a novel pathway that is upregulated in prostate cancer and promotes the initiation and progression of cancer. The aim of this study was to determine the immunohistochemical expression of ephrinB2 in prostate adenocarcinoma. METHODS: A tissue microarray comprising of prostate adenocarcinoma of different grade groups was stained with a monoclonal anti-ephrinB2 antibody (Abcam, AB201512). The tumor and endothelial cells expressing the ephrinB2 positivity were noted. The statistical analysis was performed to determine the difference in expression based on grade groups and the TNM stage. RESULTS: EphrinB2 was expressed in 40 out of 72 cases (55.5 %) of prostate adenocarcinoma and was predominantly negative in the normal prostatic tissue. There was no significant difference in the expression of ephrinB2 in various grade groups (p = 0.7) or stages (p = 0.6). CONCLUSIONS: EphrinB2 is expressed in a significant number of prostate adenocarcinoma regardless of grade and stage. Hence, there is a potential to target this molecule in the low-grade tumors with localized disease as well as high grade, high volume tumors with metastatic disease.
Authors: Jonathan W Astin; Jennifer Batson; Shereen Kadir; Jessica Charlet; Raj A Persad; David Gillatt; Jon D Oxley; Catherine D Nobes Journal: Nat Cell Biol Date: 2010-11-14 Impact factor: 28.824
Authors: S Ram Kumar; Jasbir Singh; Guangbin Xia; Valery Krasnoperov; Loubna Hassanieh; Eric J Ley; Jeffrey Scehnet; Neil G Kumar; Debra Hawes; Michael F Press; Fred A Weaver; Parkash S Gill Journal: Am J Pathol Date: 2006-07 Impact factor: 4.307
Authors: Shane P Herbert; Jan Huisken; Tyson N Kim; Morri E Feldman; Benjamin T Houseman; Rong A Wang; Kevan M Shokat; Didier Y R Stainier Journal: Science Date: 2009-10-09 Impact factor: 47.728
Authors: M Tachibana; Y Tonomoto; R Hyakudomi; M Hyakudomi; S Hattori; S Ueda; S Kinugasa; H Yoshimura Journal: Dig Liver Dis Date: 2007-07-03 Impact factor: 4.088
Authors: Jan Budczies; Frederick Klauschen; Bruno V Sinn; Balázs Győrffy; Wolfgang D Schmitt; Silvia Darb-Esfahani; Carsten Denkert Journal: PLoS One Date: 2012-12-14 Impact factor: 3.240